Preclinical studies using COPD mouse models revealed that GLP-1RA therapy significantly improved lung function and reduced both morbidity and mortality
Key Results Semaglutide vs Sitagliptin HR 0.58 (95% CI, 0.510.65) 42% lower risk 1-yr absolute risk: 5.5% vs 8.6% NNT 31 Tirzepatide vs Sitagliptin HR 0.42 (95% CI, 0.310.57) 58% lower risk 1-yr absolute risk: 3.6% vs 7.5% NNT 26 Tirzepatide vs Semaglutide HR 0.86 (95% CI, 0.701.06) no statistically significant difference Safety: No excess signal for GI, infections, or serious AEs across GLP-1/dual arms
With their lower absorption rate and frequent dosing, oral supplements can slow the process
6,9,15 What is the dose of Mounjaro
Under health secretary Robert F
A., Bozaykut, A., & zdemir, G